<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Licensetde-2020-0035.pdf Abstract At the time of writing this review, severe" exact="acute" post="respiratory coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853"/>
 <result pre="Abstract At the time of writing this review, severe acute" exact="respiratory" post="coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853 patients"/>
 <result pre="that have shown activity against SARS-CoV and Middle East coronavirus" exact="respiratory" post="syndromes are being evaluated. In particular, hydroxychloroquine, remdesivir, favipiravir,"/>
 <result pre="pandemic and where we currently stand. Graphical abstract Keywords:â€‚ COVID-19" exact="infection" post="repurposed therapies SARS-CoV-2 vaccine viruses page-count: Background Viruses are"/>
 <result pre="units to give a mainly spherical arrangement of structures [2]." exact="Viral" post="diseases continue to appear and pose a major public"/>
 <result pre="have been reported over the past 20Â years, including severe" exact="acute" post="respiratory coronavirus syndrome (SARS-CoV) from 2002 to 2003 and"/>
 <result pre="been reported over the past 20Â years, including severe acute" exact="respiratory" post="coronavirus syndrome (SARS-CoV) from 2002 to 2003 and influenza"/>
 <result pre="over the past 20Â years, including severe acute respiratory coronavirus" exact="syndrome" post="(SARS-CoV) from 2002 to 2003 and influenza A subtype"/>
 <result pre="recently, Saudi Arabia was initially infected by Middle East coronavirus" exact="respiratory" post="syndrome (MERS-CoV), a member virus of the same family"/>
 <result pre="Saudi Arabia was initially infected by Middle East coronavirus respiratory" exact="syndrome" post="(MERS-CoV), a member virus of the same family [3]."/>
 <result pre="of the same family [3]. The latest coronavirus strain, severe" exact="acute" post="respiratory coronavirus syndrome-2 (SAR-COV-2), is very infectious and highly"/>
 <result pre="the same family [3]. The latest coronavirus strain, severe acute" exact="respiratory" post="coronavirus syndrome-2 (SAR-COV-2), is very infectious and highly contagious"/>
 <result pre="coronavirus strain, severe acute respiratory coronavirus syndrome-2 (SAR-COV-2), is very" exact="infectious" post="and highly contagious and spread across the globe very"/>
 <result pre="further milestone was established when the first case of the" exact="disease" post="was recorded in the USA and not imported from"/>
 <result pre="detected in Guangdong in 2002 and 2003 with the severe" exact="acute" post="respiratory syndrome (SARS) [9]. There were two more common"/>
 <result pre="in Guangdong in 2002 and 2003 with the severe acute" exact="respiratory" post="syndrome (SARS) [9]. There were two more common types"/>
 <result pre="Guangdong in 2002 and 2003 with the severe acute respiratory" exact="syndrome" post="(SARS) [9]. There were two more common types of"/>
 <result pre="common types of CoVs, CoV-OC43, and CoV-229E, that trigger moderate" exact="infections" post="in people with an adequate immune system, before these"/>
 <result pre="is the seventh known CoV to infect humans from this" exact="viral" post="family. At first, on 12Â December 2019, an unexplained"/>
 <result pre="At first, on 12Â December 2019, an unexplained case of" exact="pneumonia" post="was identified in Wuhan. Laboratory tests eliminated suspected influenza"/>
 <result pre="and on 11Â February 2020 was assigned COVID-19 name. A" exact="total" post="of 2,355,853 recorded cases were registered, with 164,656 fatalities"/>
 <result pre="in Wuhan [3,14]. Once the first case was identified, the" exact="infection" post="was possibly spread from animal to human as a"/>
 <result pre="been reported at the beginning of April of 2020 of" exact="viral" post="re-emergence. A surge in the reported cases in Europe"/>
 <result pre="find therapeutic agents and vaccinations that are successful in the" exact="disease" post="management. Several pneumonia cases that were localized in Wuhan"/>
 <result pre="and vaccinations that are successful in the disease management. Several" exact="pneumonia" post="cases that were localized in Wuhan in December 2019"/>
 <result pre="successful in the disease management. Several pneumonia cases that were" exact="localized" post="in Wuhan in December 2019 were identified, and sources"/>
 <result pre="pneumonia, while on 31Â December 2019, 27 cases of extreme" exact="viral pneumonia" post="were officially confirmed [15]. Etiological studies of people that"/>
 <result pre="while on 31Â December 2019, 27 cases of extreme viral" exact="pneumonia" post="were officially confirmed [15]. Etiological studies of people that"/>
 <result pre="from wild bats and group 2 Î²-CoVs, which comprises severe" exact="acute" post="respiratory syndrome-related coronavirus (SARS-COV), was announced to be developed"/>
 <result pre="wild bats and group 2 Î²-CoVs, which comprises severe acute" exact="respiratory" post="syndrome-related coronavirus (SARS-COV), was announced to be developed on"/>
 <result pre="severe problems in the prevention and control of this extremely" exact="infectious disease." post="From 17 January till 23 February 2003, the Chinese"/>
 <result pre="Based on the structural studies of Î±- and Î²-coronavirus, the" exact="viral" post="genome encodes many structural proteins; including the spike (S)"/>
 <result pre="by serine protease TMPRSS211, formed by the host cell. The" exact="viral" post="genome also encodes a variety of nonstructural proteins such"/>
 <result pre="coronaviral principal protease (3CLpro)Â and papain-like protease (PLpro) [21]. The" exact="viral" post="genome is discharged as a positive sense of a"/>
 <result pre="uses host cell protein translation machinery (ribosomes) to produce the" exact="viral" post="polyprotein and then cleaves it into effector proteins through"/>
 <result pre="viral polyprotein and then cleaves it into effector proteins through" exact="viral" post="proteases 3CLpro and PLpro [22]. The most complex component"/>
 <result pre="unrecognized human-to-human transmission. Such adaptations allowed the pandemic of the" exact="disease" post="once it has been acquired [26,28]. SARS-CoV-2 infection is"/>
 <result pre="allowed the pandemic of the disease once it has been" exact="acquired" post="[26,28]. SARS-CoV-2 infection is primarily thought to transmit from"/>
 <result pre="of the disease once it has been acquired [26,28]. SARS-CoV-2" exact="infection" post="is primarily thought to transmit from human-to-human among individuals"/>
 <result pre="has been reported that people are known to be more" exact="infectious" post="when they are most (sickest) symptomatic. Besides, an individual"/>
 <result pre="quickly and sustainably among individuals [29]. Symptoms of catching an" exact="infection" post="Information from public care bodies, reviews and guidelines provide"/>
 <result pre="the strength of the immune system of the infected individual." exact="Acute" post="influenza, ARDS, sepsis and septic shock are among severe"/>
 <result pre="system of the infected individual. Acute influenza, ARDS, sepsis and" exact="septic shock" post="are among severe health symptoms. A definite pattern in"/>
 <result pre="a week, infected individual health outcomes have unexpectedly worsened, as" exact="respiratory" post="failure has declined rapidly. The extreme respiratory failure conditions"/>
 <result pre="unexpectedly worsened, as respiratory failure has declined rapidly. The extreme" exact="respiratory" post="failure conditions and medical requirements of sepsis and septic"/>
 <result pre="extreme respiratory failure conditions and medical requirements of sepsis and" exact="septic shock" post="should be taken seriously [3]. Patients with uncomplicated (mild"/>
 <result pre="have signs that include mild fever, dry cough, sore throat," exact="respiratory" post="irritation, fatigue, stomach aches and malaise, whereas reported dyspnea"/>
 <result pre="dyspnea in patients were asymptomatic [15]. Nonrespiratory signs such as" exact="diarrhea" post="are challenging to identify relative to prior HCoV infections."/>
 <result pre="are challenging to identify relative to prior HCoV infections. Moderate" exact="pneumonia" post="respiratory signs such as cough and shortness of breath"/>
 <result pre="challenging to identify relative to prior HCoV infections. Moderate pneumonia" exact="respiratory" post="signs such as cough and shortness of breath (or"/>
 <result pre="etc.) were reported for patients with some cases [13]. Extreme" exact="pneumonia" post="fever is caused by heavy illnesses, respiratory depression or"/>
 <result pre="cases [13]. Extreme pneumonia fever is caused by heavy illnesses," exact="respiratory" post="depression or hypoxia (SpO2 &amp;lt;90%Â in the room). Fever"/>
 <result pre="[13]. Extreme pneumonia fever is caused by heavy illnesses, respiratory" exact="depression" post="or hypoxia (SpO2 &amp;lt;90%Â in the room). Fever is"/>
 <result pre="pneumonia fever is caused by heavy illnesses, respiratory depression or" exact="hypoxia" post="(SpO2 &amp;lt;90%Â in the room). Fever is consistent with"/>
 <result pre="illnesses, respiratory depression or hypoxia (SpO2 &amp;lt;90%Â in the room)." exact="Fever" post="is consistent with extreme pneumonia [30]. Nevertheless, fever signs"/>
 <result pre="(SpO2 &amp;lt;90%Â in the room). Fever is consistent with extreme" exact="pneumonia" post="[30]. Nevertheless, fever signs thought to be correctly recognized"/>
 <result pre="disease. In children, cyanosis can occur. The description includes a" exact="psychiatric condition," post="and radiological terminology is used to remove complications with"/>
 <result pre="for this diagnosis [13]. This condition indicates a severe new" exact="respiratory" post="problem and a deterioration of a respiratory feature that"/>
 <result pre="a severe new respiratory problem and a deterioration of a" exact="respiratory" post="feature that has already been established. The degree of"/>
 <result pre="respiratory feature that has already been established. The degree of" exact="hypoxia" post="in various types of acute respiratory distress syndrome (ARDS)"/>
 <result pre="been established. The degree of hypoxia in various types of" exact="acute" post="respiratory distress syndrome (ARDS) is distinct [31]. Furthermore, sepsis"/>
 <result pre="established. The degree of hypoxia in various types of acute" exact="respiratory" post="distress syndrome (ARDS) is distinct [31]. Furthermore, sepsis is"/>
 <result pre="degree of hypoxia in various types of acute respiratory distress" exact="syndrome" post="(ARDS) is distinct [31]. Furthermore, sepsis is a life-threatening"/>
 <result pre="functional organ changes), and signs of multi-organ shock presented as" exact="hyperbilirubinemia" post="laboratory results [31]. Clinical progression &amp;amp; diagnosis The quest"/>
 <result pre="links and recommendations for common knowledge (WHO, Europe Center of" exact="Disease" post="Control [CDC], US CDC, US FDA). Six diagnostic protocols"/>
 <result pre="Table 1. SARS-CoV-2, SARS-CoV and MERS-CoV diagnose systematic assessment results." exact="Viral" post="strain Test Samples References Ref. SARS-CoV-2 rRT-PCR; E gene"/>
 <result pre="SARS-CoV-2 rRT-PCR; E gene assay; confirmatory testing: RdRp gene assay" exact="Respiratory" post="samples from hospitalized patients Â [33] SARS-CoV-2 COVID-19 IgG/IgM"/>
 <result pre="based on gold nanoparticles Saliva swab Oxford Suzhou Centre for" exact="Advanced" post="Research (OSCAR) Â SARS-CoV-2 A colorimetric assay based on"/>
 <result pre="clinical sera collected from patients with probable or suspected SARS," exact="dengue fever," post="autoimmune diseases Â [40] SARS-CoV RT-PCR 274 clinical sera"/>
 <result pre="collected from patients with probable or suspected SARS, dengue fever," exact="autoimmune diseases" post="Â [40] SARS-CoV RT-PCR 274 clinical sera collected from"/>
 <result pre="the SARS-CoV-2 appeared, real-time polymerase chain reactions (RT-PCR) remained the" exact="primary" post="diagnostic tool for the latest viral strain among the"/>
 <result pre="reactions (RT-PCR) remained the primary diagnostic tool for the latest" exact="viral" post="strain among the different diagnostic platforms. One research addressed"/>
 <result pre="diagnosing patients with SARS-CoV-2 from 16 experimental trials [33,42]. The" exact="respiratory" post="tests were shown to be positive for the virus,"/>
 <result pre="the virus, although the serum in the early days of" exact="infection" post="was negative. This has indicated that patients had elevated"/>
 <result pre="(SARS-CoV-2, SARS-CoV and SARS coronavirus like) with coronaviruses [11]. Extracted" exact="viral" post="RNA from SARS-CoV would be used as a supportive,"/>
 <result pre="or treatment may result in false-negative results due to insufficient" exact="viral" post="biological material in the sample. RNA viruses may also"/>
 <result pre="(N) and spike (S) ) that are bound to a" exact="viral" post="protein [33,45]. If either ELISA confirms whether a clinical"/>
 <result pre="that low titers of antibodies may be correlated with high" exact="viral" post="load in a second week or with delayed antibody"/>
 <result pre="nucleic amplification tests (NAAT) are not given or available [30]." exact="Structural" post="proteins as vaccine candidates The first and complete genome"/>
 <result pre="available [30]. Structural proteins as vaccine candidates The first and" exact="complete" post="genome sequence of SARS-COV-2, which provides the key to"/>
 <result pre="the key to the possible structure and glycosylation pattern of" exact="viral" post="proteins and thus modes of association with a host"/>
 <result pre="enclosed nucleic acid. The N-protein has the following roles in" exact="viral" post="life-cycle: associates with the viral membrane protein during viral"/>
 <result pre="has the following roles in viral life-cycle: associates with the" exact="viral" post="membrane protein during viral assembly, and facilitates the production"/>
 <result pre="in viral life-cycle: associates with the viral membrane protein during" exact="viral" post="assembly, and facilitates the production and folding of RNA,"/>
 <result pre="production and folding of RNA, this plays a part in" exact="viral" post="budding. S protein has two main tasks that enable"/>
 <result pre="entrance into the host's cell by helping to connect the" exact="viral" post="cell membranes with the host's membranes [20,47]. ACE2 is"/>
 <result pre="its glycosylation, is identical to many other coronaviruses [20]. The" exact="primary" post="host interacting protein is essential for cell adhesion (such"/>
 <result pre="glycoprotein and glycan shield patterns that have significant effects on" exact="viral" post="camouflage and mode of cell entry, which could help"/>
 <result pre="of cell entry, which could help the production of new" exact="infection" post="screening, vaccinations and treatment. Another report of the COVID-19"/>
 <result pre="2 [49]. Figure 2. Schematic representation of the novel SARS-CoV-2" exact="viral" post="capsid. The coronavirus spike (S) protein mediates membrane fusion"/>
 <result pre="spike glycoprotein, interacting with several host cell proteins, is the" exact="primary" post="motive for the trafficking in and the hijacking of"/>
 <result pre="is the crucial component in the immune regulatory pathway of" exact="viral" post="infections responsible for the cleavage of amino-terminal dipeptides from"/>
 <result pre="the crucial component in the immune regulatory pathway of viral" exact="infections" post="responsible for the cleavage of amino-terminal dipeptides from polypeptides"/>
 <result pre="virus-like particles). It can take more than 1 year to" exact="complete" post="clinical trials for most candidates with the exception of"/>
 <result pre="with the exception of those sponsored by the Coalition for" exact="Epidemic" post="Preparedness Technologies (CEPI). However, the BGI kit met the"/>
 <result pre="[55]. The trials will be finished by December 2020 (two" exact="Russian" post="studies) [54] and December 2021 (German study) [54]. Medicago"/>
 <result pre="of Queensland's utilizing subunit recombinant expression of potential vaccines [56â€&quot;63]." exact="Essential" post="proteins &amp;amp; their roles in viral infection SARS-CoV-2, based"/>
 <result pre="of potential vaccines [56â€&quot;63]. Essential proteins &amp;amp; their roles in" exact="viral infection" post="SARS-CoV-2, based on full-length phylogenetic genome review, is found"/>
 <result pre="potential vaccines [56â€&quot;63]. Essential proteins &amp;amp; their roles in viral" exact="infection" post="SARS-CoV-2, based on full-length phylogenetic genome review, is found"/>
 <result pre="among the structural components of CoVs. The spikes on the" exact="viral" post="surface are produced by S protein homo-trimers, which direct"/>
 <result pre="1 [13]. Preventive approaches rely on hospital separation and diligent" exact="infection" post="management, including effective preventive intervention and emergency treatment for"/>
 <result pre="following general guidelines: prevent intimate contact with people having severe" exact="respiratory" post="infections. Always wash hands, especially after being in contact"/>
 <result pre="broad coverage, and social media transported the news of the" exact="disease" post="much faster than previously reported. Over the years, websites"/>
 <result pre="websites such as FluTrackers.com, ProMED (promedmail.org), and others have allowed" exact="disease" post="knowledge to be gathered from all around the world"/>
 <result pre="the world to link up-to-date sequential details and illustrate critical" exact="disease" post="acknowledgements. The opportunity to exchange news reports and pieces"/>
 <result pre="of SARS were learned. Current treatments adapted to manage the" exact="disease" post="Until the time of this review, there are no"/>
 <result pre="moment in the standard clinical practices of China for SARS-CoV-2" exact="infection" post="[27]. However, the validity of using these compounds should"/>
 <result pre="settings. However, due to risks of deterioration in health, sudden" exact="respiratory" post="failure and isolation failure, inpatients setting are preferred when"/>
 <result pre="is indicated at a rate of 5 L/min to counteract" exact="respiratory" post="distress, hypoxemia or shock. It should be continued to"/>
 <result pre="to reach target oxygen saturation &amp;gt;94% during resuscitation, &amp;gt;90% in" exact="stable" post="cases for most patients and &amp;gt;95% for pregnant women."/>
 <result pre="ventilation should be given for patients with severe deterioration in" exact="respiratory" post="functions such as acute respiratory distress syndrome (ARDS) [43]."/>
 <result pre="for patients with severe deterioration in respiratory functions such as" exact="acute" post="respiratory distress syndrome (ARDS) [43]. Complications should be expected,"/>
 <result pre="patients with severe deterioration in respiratory functions such as acute" exact="respiratory" post="distress syndrome (ARDS) [43]. Complications should be expected, including"/>
 <result pre="severe deterioration in respiratory functions such as acute respiratory distress" exact="syndrome" post="(ARDS) [43]. Complications should be expected, including sepsis, acute"/>
 <result pre="distress syndrome (ARDS) [43]. Complications should be expected, including sepsis," exact="acute" post="respiratory distress syndrome, septic shock, acute kidney injury, acute"/>
 <result pre="syndrome (ARDS) [43]. Complications should be expected, including sepsis, acute" exact="respiratory" post="distress syndrome, septic shock, acute kidney injury, acute cardiac"/>
 <result pre="Complications should be expected, including sepsis, acute respiratory distress syndrome," exact="septic shock," post="acute kidney injury, acute cardiac injury, acute liver injury"/>
 <result pre="be expected, including sepsis, acute respiratory distress syndrome, septic shock," exact="acute" post="kidney injury, acute cardiac injury, acute liver injury and"/>
 <result pre="expected, including sepsis, acute respiratory distress syndrome, septic shock, acute" exact="kidney injury," post="acute cardiac injury, acute liver injury and should be"/>
 <result pre="sepsis, acute respiratory distress syndrome, septic shock, acute kidney injury," exact="acute" post="cardiac injury, acute liver injury and should be managed"/>
 <result pre="distress syndrome, septic shock, acute kidney injury, acute cardiac injury," exact="acute" post="liver injury and should be managed according to their"/>
 <result pre="that NSAIDs may upregulate ACE receptors, which could worsen the" exact="disease" post="progression [71]. Examples of supportive management are described briefly"/>
 <result pre="Another clinical study at the national clinical research center for" exact="infectious diseases" post="(the Third People's Hospital of Shenzhen), Shenzhen, China, has"/>
 <result pre="empirical antibiotics are varied depending on local epidemiology and common" exact="bacterial" post="pathogens [17]. For example, a retrospective study from Jinyintan"/>
 <result pre="still no detailed guidelines for SARS-CoV-2 patients with comorbidities, including" exact="cardiovascular" post="diseases, asthma, and cancer. However, current recommendations are still"/>
 <result pre="drugs have been used before to control and treat previous" exact="viral" post="outbreaks, including the SARS-CoV outbreak in 2003 and the"/>
 <result pre="determine their efficiency in improving patients' survival and reducing the" exact="viral" post="load of SARS-CoV-2 infection [77]. The investigations include antiviral"/>
 <result pre="improving patients' survival and reducing the viral load of SARS-CoV-2" exact="infection" post="[77]. The investigations include antiviral drugs such as lopinavir,"/>
 <result pre="China National Health Commission (NHC) for the study of SARS-CoV-2-induced" exact="pneumonia" post="for prevention, diagnostic and care [78]. In silico, in"/>
 <result pre="antiviral activity [79]. Antiviral agents Lopinavir (LPV) is a HIV" exact="type 1" post="aspartate protease inhibitor while ritonavir (RTV) is usually combined"/>
 <result pre="Yin-Tan Hospital, Wuhan, on 199 seriously ill patients of SARS-CoV-2" exact="infection" post="[80]. Male and nonpregnant patients of 18Â years or"/>
 <result pre="patients have an oxygen saturation of 94% or less with" exact="pneumonia" post="confirmed by chest imagining. They were divided into two"/>
 <result pre="oxygen saturation of 94% or less with pneumonia confirmed by" exact="chest" post="imagining. They were divided into two groups: a control"/>
 <result pre="and 25%, respectively [81]. No differences in the percentages of" exact="viral" post="RNA detection was found at different times points in"/>
 <result pre="Patients with severe conditions, including RR &amp;gt;30, oxygen saturation &amp;lt;93%," exact="respiratory" post="failure, shock, and end-stage kidney or liver diseases, were"/>
 <result pre="Standard care was given to both groups. Clinical outcomes include" exact="viral" post="clearance (two constitutive negative results on qPCR detection throughout"/>
 <result pre="negative results on qPCR detection throughout 24Â h), changes in" exact="chest" post="imaging (improvement in CT scan for lung parenchyma based"/>
 <result pre="effects (by questionaries and lab results). The median time of" exact="viral" post="clearance was significantly lower in FPV group compared with"/>
 <result pre="lab results). The median time of viral clearance was significantly" exact="lower" post="in FPV group compared with the LPV/RTV group 4"/>
 <result pre="further the role of FPV in the management of SARS-CoV-2" exact="infection" post="(NCT04303299, NCT04310228 and NCT04273763). FPV is being investigated as"/>
 <result pre="It also showed promising in vitro activities by blocking the" exact="viral infection" post="of SARS-CoV-2, as demonstrated by Wang M. et al.,"/>
 <result pre="also showed promising in vitro activities by blocking the viral" exact="infection" post="of SARS-CoV-2, as demonstrated by Wang M. et al.,"/>
 <result pre="clinical case study for the first patient diagnosed with SARS-CoV-2" exact="infection" post="in USA has shown promising effectiveness of RDV [74]."/>
 <result pre="NCT04280705, NCT04315948 and NCT04302766). The studies have differences in patients" exact="disease" post="conditions (mild, moderate and severe), treatment durations (5, 9"/>
 <result pre="on day 13 of symptoms and showed significant improvement in" exact="respiratory" post="symptoms (extubation) after 6Â h of RDV first dose"/>
 <result pre="recruiting patients to determine the efficacy of RBV for SARS-CoV-2" exact="infection" post="at the University of Hong Kong, Queen Mary Hospital."/>
 <result pre="arbidol to or LPV/RTV treatment significantly provided additional benefits on" exact="viral" post="clearance and patients' clinical outcomes. Arbidol was administered at"/>
 <result pre="mg) orally every 12Â h. The combination group achieved higher" exact="viral" post="clearance rates at days 7 and 14 compared with"/>
 <result pre="School of Medicine [92]. This is maybe important as earlier" exact="viral" post="clearance is associated with more prevention of severe lung"/>
 <result pre="investigating the role of arbidol in the management of SARS-CoV-2" exact="pneumonia" post="in different combinations, including NCT04260594 and NCT04286503 [94]. Clevudine"/>
 <result pre="currently being investigated extensively for its promising activity against SARS-CoV-2" exact="infection" post="[96,97]. CQ is an old antimalarial drug with limited"/>
 <result pre="SARS-CoV-2 infection [96,97]. CQ is an old antimalarial drug with" exact="limited" post="use due to its resistance as well as poisoning"/>
 <result pre="(HCQ) was developed later and showed better clinical safety and" exact="lower" post="risks of toxicities [99]. HCQ is also an option"/>
 <result pre="[99]. HCQ is also an option for the management of" exact="autoimmune diseases," post="including rheumatoid arthritis (RA) and systemic lupus erythematosus. HCQ"/>
 <result pre="also an option for the management of autoimmune diseases, including" exact="rheumatoid arthritis" post="(RA) and systemic lupus erythematosus. HCQ is a highly"/>
 <result pre="an option for the management of autoimmune diseases, including rheumatoid" exact="arthritis" post="(RA) and systemic lupus erythematosus. HCQ is a highly"/>
 <result pre="the management of autoimmune diseases, including rheumatoid arthritis (RA) and" exact="systemic" post="lupus erythematosus. HCQ is a highly available drug with"/>
 <result pre="management of autoimmune diseases, including rheumatoid arthritis (RA) and systemic" exact="lupus erythematosus." post="HCQ is a highly available drug with a low"/>
 <result pre="in vitro level, HCQ showed significant inhibition of the SAR-CoV-2" exact="infection" post="[46]. CQ and HCQ resulted in significant antiviral cytotoxicity"/>
 <result pre="[46]. CQ and HCQ resulted in significant antiviral cytotoxicity in" exact="African" post="green monkey kidney VeroE6 cells (ATCC-1586) (CC50 273.20 and"/>
 <result pre="273.20 and 249.50Â Î¼M, respectively). The two compounds reduced the" exact="viral" post="RNA copy number, with CQ being significantly more potent"/>
 <result pre="mechanisms of action include interfering with the pH-dependent steps of" exact="viral" post="replication by increasing the pH of intracellular vesicles such"/>
 <result pre="[102]. WangÂ et al. have demonstrated potent blocking of SARS-COV-2" exact="viral infection" post="by CQ (EC50Â =Â 1.13Â Î¼M; CC50Â &amp;gt;100Â Î¼M,"/>
 <result pre="WangÂ et al. have demonstrated potent blocking of SARS-COV-2 viral" exact="infection" post="by CQ (EC50Â =Â 1.13Â Î¼M; CC50Â &amp;gt;100Â Î¼M,"/>
 <result pre="in reversing the hyperinflammation and cytokine storm associated with SARS-COV-2" exact="pneumonia" post="[102]. On the clinical levels, until 22 March, several"/>
 <result pre="Registry to test the CQ or HCQ efficiency on SARS-CoV-2" exact="infection" post="[97]. The clinical outcomes include time to clinical recovery,"/>
 <result pre="showed excellent results compared with control. CQ treated patients showed" exact="lower" post="viral load, better CT imaging, and shorter disease period"/>
 <result pre="excellent results compared with control. CQ treated patients showed lower" exact="viral" post="load, better CT imaging, and shorter disease period [97]."/>
 <result pre="patients showed lower viral load, better CT imaging, and shorter" exact="disease" post="period [97]. The ongoing clinical studies, efficacy and safety"/>
 <result pre="alone in treating SARS-CoV-2 are being investigated in ChiCTR2000030054 (a" exact="total" post="80 patients are enrolled), ChiCTR2000029992 (three groups: CQ, HCQ"/>
 <result pre="tablets combined with CQ phosphate in the treatment of coronavirus" exact="pneumonia" post="is being investigated in the ChiCTR2000030987 clinical trial. In"/>
 <result pre="patient allergies, glucose-6-phosphate dehydrogenase (G6PD) deficiency, previous history of retinopathy," exact="cardiomyopathy" post="(QT prolongation)Â or end-stage kidney disease [96]. A recent"/>
 <result pre="deficiency, previous history of retinopathy, cardiomyopathy (QT prolongation)Â or end-stage" exact="kidney disease" post="[96]. A recent protocol approved by the office of"/>
 <result pre="previous history of retinopathy, cardiomyopathy (QT prolongation)Â or end-stage kidney" exact="disease" post="[96]. A recent protocol approved by the office of"/>
 <result pre="recent protocol approved by the office of National Clinical Advisor," exact="acute" post="hospital division, recommended the use of CQ 500Â mg"/>
 <result pre="About 36 patients were included, including asymptomatic patients, patients with" exact="upper" post="respiratory tract symptoms, and patients with lower respiratory tract"/>
 <result pre="36 patients were included, including asymptomatic patients, patients with upper" exact="respiratory" post="tract symptoms, and patients with lower respiratory tract symptoms"/>
 <result pre="patients, patients with upper respiratory tract symptoms, and patients with" exact="lower" post="respiratory tract symptoms were included. About 20 patients received"/>
 <result pre="patients with upper respiratory tract symptoms, and patients with lower" exact="respiratory" post="tract symptoms were included. About 20 patients received HCQ"/>
 <result pre="the innate immune system of the patient to fight the" exact="infection" post="(immune senescence). SARS-CoV-2 blocks the interferon pathway and prevents"/>
 <result pre="The rationale of using immunosuppressants in the management of SARS-CoV-2-associated" exact="pneumonia" post="comes from several reports of cases of hyper inflammation"/>
 <result pre="[112]. Investigating its role in the management of SARS-CoV-2 associated" exact="pneumonia" post="is based on the inflammation and cytokine storm detected"/>
 <result pre="and other mediators may have potential clinical benefits in reversing" exact="respiratory" post="dysfunction in those patients. A retrospective study from China"/>
 <result pre="fever (100%), lowering of oxygen intake 75% and improvement in" exact="respiratory" post="function. Tocilizumab normalized lymphocytes levels 52.6%, significantly decreased the"/>
 <result pre="critical SARS-CoV-2 infections. However, this study is observational study with" exact="limited" post="number of patients. According to clinical trials are currently"/>
 <result pre="[114]. A clinical trial (TOCIVID-19, NCT04317092) supported by the National" exact="Cancer" post="Institute was recently registered in Clinicaltrials.gov to investigate the"/>
 <result pre="tocilizumab 8 mg/kg in patients with SARS-CoV-2 severe multifocal interstitial" exact="pneumonia" post="[116]. Two more Chinese studies are also investigating tocilizumab"/>
 <result pre="versus FPV alone versus tocilizumab alone for treatment of SARS-CoV-2" exact="infection" post="[117]. Sarilumab is another IL-6 blocker that is used"/>
 <result pre="is usually associated with several risks, including the development of" exact="secondary" post="infections and severe allergic reactions. Such risks should be"/>
 <result pre="usually associated with several risks, including the development of secondary" exact="infections" post="and severe allergic reactions. Such risks should be considered"/>
 <result pre="which is an essential process for the development of new" exact="blood vessels" post="to supply cancer cells with oxygen and nutrients [120]."/>
 <result pre="process for the development of new blood vessels to supply" exact="cancer" post="cells with oxygen and nutrients [120]. Bevacizumab showed productive"/>
 <result pre="[120]. Bevacizumab showed productive anticancer activities against colorectal, kidney, lung," exact="breast" post="and head and neck cancers [111]. Bevacizumab is also"/>
 <result pre="productive anticancer activities against colorectal, kidney, lung, breast and head" exact="and neck" post="cancers [111]. Bevacizumab is also being studied as a"/>
 <result pre="on 20 patients. However, the therapeutic benefits of bevacizumab are" exact="limited" post="by possible serious events associated with its use. Bevacizumab"/>
 <result pre="in new-onset hypertension, bleeding, delaying wound healing, thromboembolic events and" exact="bowel" post="perforations [111]. These risks should be considered while repurposing"/>
 <result pre="a TNF inhibitor and may show effective inhibition of SARS-CoV-2" exact="pneumonia" post="[71]. Corticosteroids (methylprednisolone in particular) Previously, corticosteroids have been"/>
 <result pre="hand, corticosteroids may suppress the immune response and delay the" exact="viral" post="clearance of SARS-CoV-2 [71]. To investigate their exact effects,"/>
 <result pre="was dropped to less than 60%, and the patient developed" exact="cardiac arrest" post="and died [27]. A study included 80 patients with"/>
 <result pre="died [27]. A study included 80 patients with confirmed SARS-CoV-2" exact="infection" post="received treatment of a single antibiotic (moxifloxacin) and RBV"/>
 <result pre="Another study was conducted on 46 patients with confirmed SARS-CoV-2" exact="infection" post="who received standard care of oxygen, cough relief, antiviral"/>
 <result pre="of SARS-CoV-2 is still controversial. According to the Centers for" exact="Disease" post="Control and Prevention, corticosteroids are not preferred as they"/>
 <result pre="not preferred as they may be associated with prolongation of" exact="viral" post="replication, as noted in previous MERS-CoV outbreak [68]. Ongoing"/>
 <result pre="patients. These studies include NCT04244591 (for critically-ill patients with severe" exact="acute" post="respiratory failure (Steroids-SARI) in Beijing, China), NCT04263402 (to compare"/>
 <result pre="These studies include NCT04244591 (for critically-ill patients with severe acute" exact="respiratory" post="failure (Steroids-SARI) in Beijing, China), NCT04263402 (to compare the"/>
 <result pre="of different hormone doses in the treatment of SARS-CoV-2 severe" exact="pneumonia" post="in Wuhan, Hubei, China), and NCT04273321 (to determine efficacy"/>
 <result pre="previous reports about the effectiveness of these interventions in curing" exact="pneumonia" post="in general. The study urges the implantation of clinical"/>
 <result pre="the potential efficacy of ivermectin against SAR-COV-2. 5000-fold reduced the" exact="viral" post="load (in 2-h post-infection with SARS-CoV-2 Vero-hSLAM cells) after"/>
 <result pre="yet) The discovery and development of new molecules against SARS-CoV-2" exact="infection" post="need time [129]. Besides, in silico discovery of molecules"/>
 <result pre="these potential therapies was based on their role in similar" exact="viral" post="infections on the corresponding targets. Anti-inflammatory therapies Inflammation is"/>
 <result pre="potential therapies was based on their role in similar viral" exact="infections" post="on the corresponding targets. Anti-inflammatory therapies Inflammation is a"/>
 <result pre="response of the immune system during the earliest stages of" exact="viral" post="infections [130]. As a result, the anti-inflammatory drug is"/>
 <result pre="of the immune system during the earliest stages of viral" exact="infections" post="[130]. As a result, the anti-inflammatory drug is a"/>
 <result pre="As a result, the anti-inflammatory drug is a choice for" exact="viral" post="infections, including SARS-CoV-2 infection. Few studies discussed anti-inflammatory therapies"/>
 <result pre="therapies as an option to reduce the symptoms of SARS-CoV-2" exact="infection" post="with baricitinib, and melatonin being the most related [131]."/>
 <result pre="for anti-inflammatory drugs that could be potential therapies for SARS-CoV-2" exact="infection" post="[132]. SAR-COV-2 enters lung cells by ACE2-mediated invasion. AP2-associated"/>
 <result pre="potential anti-inflammatory drug to relieve the symptoms of SARS-CoV-2 infection." exact="Viral" post="infections cause injury of the immune system that is"/>
 <result pre="anti-inflammatory drug to relieve the symptoms of SARS-CoV-2 infection. Viral" exact="infections" post="cause injury of the immune system that is commonly"/>
 <result pre="and has been previously encouraged to be used for Ebola" exact="viral infection" post="[134]. As suggested by ChengÂ et al., melatonin could"/>
 <result pre="has been previously encouraged to be used for Ebola viral" exact="infection" post="[134]. As suggested by ChengÂ et al., melatonin could"/>
 <result pre="et al., melatonin could reduce the clinical symptoms of SARS-CoV-2" exact="infection" post="and prolong the survival time for the patient. Angiotensin"/>
 <result pre="receptor blocking therapies As mentioned previously, SARS-CoV-2 gets into the" exact="pulmonary" post="cells after binding to the ACE2 receptor domain [135]."/>
 <result pre="to the ACE2 receptor domain [135]. However, due to the" exact="limited" post="number of studies, it is still unclear how ACE2"/>
 <result pre="it is still unclear how ACE2 is modified in SARS-CoV-2" exact="infection" post="[32,135]. Kruse has suggested that therapies that block the"/>
 <result pre="domain could be studied for their potential effectiveness against SARS-CoV-2" exact="infection" post="[136]. For example, using the small receptor-binding domain (RBD)"/>
 <result pre="for the function of proteases 3CLpro and Plpro in SARS-CoV" exact="infection" post="[141]. These candidates are also undergoing studies in research"/>
 <result pre="[141,142]. Î±-ketoamide inhibitors were previously synthesized and tested against MERS-CoV" exact="infection" post="by Liu research group. Î±-ketoamide derivatives have shown picomolar"/>
 <result pre="inhibitor and considered Î±-ketoamide inhibitors as promising agents for SARS-CoV-2" exact="infection" post="[140]. Traditional Chinese medicines therapy Traditional Chinese medicines (TCMs)"/>
 <result pre="group of diseases [143]. TCMs that have shown activity against" exact="viral" post="infections, specifically lung infections, could be potential therapies for"/>
 <result pre="based on historical records on the prevention and treatment of" exact="infections" post="using TCM, TCM prevention programs issued by Chinese health"/>
 <result pre="databases, and preliminary literature results about using TCM in other" exact="respiratory" post="viral infections [147]. Based on the results, Jian-PingÂ et"/>
 <result pre="and preliminary literature results about using TCM in other respiratory" exact="viral" post="infections [147]. Based on the results, Jian-PingÂ et al."/>
 <result pre="preliminary literature results about using TCM in other respiratory viral" exact="infections" post="[147]. Based on the results, Jian-PingÂ et al. have"/>
 <result pre="as different TCMs that have been previously used in treating" exact="respiratory" post="viral infections by an in silico screening. Therapies in"/>
 <result pre="different TCMs that have been previously used in treating respiratory" exact="viral" post="infections by an in silico screening. Therapies in research"/>
 <result pre="TCMs that have been previously used in treating respiratory viral" exact="infections" post="by an in silico screening. Therapies in research &amp;amp;"/>
 <result pre="use in multiple oncology gastrointestinal and indications RedHill Biopharma https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&amp;amp;LNGID=1&amp;amp;TMID=178&amp;amp;FID=2432&amp;amp;PID=0&amp;amp;IID=13253" exact="Antibody" post="cocktail therapy â€&quot; Regeneron Pharmaceuticals https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody Conclusion The review"/>
 <result pre="antimalarials and immunotherapeutics aimed at diverse molecular associations linked to" exact="infection" post="and replication. This review focuses primarily on agents reported"/>
 <result pre="successful drugs and vaccinations against current and possible future SARS-CoV-2" exact="infections" post="and other potentially pathogenic virus outbreaks to minimize the"/>
 <result pre="available, patient management and global response from enforced curfew to" exact="total" post="lockdown that we are witnessing around the globe. Only"/>
 <result pre="necessity and willingness to deliver high-quality data even in a" exact="disease" post="outbreak. To date, no successful treatments have been identified"/>
 <result pre="of cell phone touch tracing will contribute to a permanent" exact="disease" post="elimination. 6.WrappD , WangN , CorbettKSet al.Cryo-EM structure of"/>
 <result pre="(2010). 8.DrexlerJF , Gloza-RauschF , GlendeJet al.Genomic characterization of severe" exact="acute" post="respiratory syndrome-related coronavirus in European bats and classification of"/>
 <result pre="8.DrexlerJF , Gloza-RauschF , GlendeJet al.Genomic characterization of severe acute" exact="respiratory" post="syndrome-related coronavirus in European bats and classification of coronaviruses"/>
 <result pre="coronavirus in European bats and classification of coronaviruses based on" exact="partial" post="RNA-dependent RNA polymerase gene sequences. J. Virol.84(21), 11336â€&quot;11349 (2010).20686038"/>
 <result pre="LaiS , PoonLet al.Coronavirus as a possible cause of severe" exact="acute" post="respiratory syndrome. Lancet361(9366), 1319â€&quot;1325 (2003).12711465 11.ZakiAM , Van BoheemenS"/>
 <result pre=", PoonLet al.Coronavirus as a possible cause of severe acute" exact="respiratory" post="syndrome. Lancet361(9366), 1319â€&quot;1325 (2003).12711465 11.ZakiAM , Van BoheemenS ,"/>
 <result pre=", FouchierRAIsolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi Arabia. N. Engl. J. Med.367(19), 1814â€&quot;1820 (2012)."/>
 <result pre="Engl. J. Med.367(19), 1814â€&quot;1820 (2012). 23075143 â€¢ Stepping point of" exact="viral" post="isolation. 12.ImaiN , DorigattiI , CoriA , DonnellyC ,"/>
 <result pre=", DonnellyC , RileyS , FergusonNMReport 2: Estimating the potential" exact="total" post="number of novel Coronavirus cases in Wuhan City, China.Imperial"/>
 <result pre="progression. Int. J. Infect. Dis. (2020). 15.collab: RVB. Division of" exact="viral" post="diseases. Real-time rt-pcr panel for detection 2019- novel coronavirus."/>
 <result pre="Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus" exact="Disease" post="2019 (COVID-19). J. Microbiol. Biotechnol.30(3), 313â€&quot;324 (2020).32238757 19.ChenZ ,"/>
 <result pre="LuYet al.From SARS-CoV to Wuhan 2019-nCoV Outbreak: Similarity of Early" exact="Epidemic" post="and Prediction of Future Trends. Cell-Host-Microbe-D-20-00063 (2020). 10.2139/ssrn.3528722 20.HoffmannM"/>
 <result pre="271â€&quot;280.e8 (2020). 32142651 â€¢â€¢ This is a fundamental study on" exact="viral" post="entry essential to designing an antiviral and understanding the"/>
 <result pre="of SARS coronavirus. J. Virol.94(7), (2020). â€¢ Fundamental research on" exact="viral" post="structure and genome arrangement and important aspect in developing"/>
 <result pre="aspect in developing suitable therapeutics. 25.PengZ , Xing-LouY , Xian-GuangWA" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="26.WuF , ZhaoS , YuBA new coronavirus associated with human" exact="respiratory" post="disease in China. Nature579(7798), 265â€&quot;269 (2020).32015508 27.XuZ , ShiL"/>
 <result pre=", ZhaoS , YuBA new coronavirus associated with human respiratory" exact="disease" post="in China. Nature579(7798), 265â€&quot;269 (2020).32015508 27.XuZ , ShiL ,"/>
 <result pre=", ShiL , WangYet al.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndrome. Lancet Respir. Med.8(4), 420â€&quot;422 (2020). .32085846"/>
 <result pre="ShiL , WangYet al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndrome. Lancet Respir. Med.8(4), 420â€&quot;422 (2020). .32085846 28.WuJ"/>
 <result pre="pii: ciaa199 (2020) (Epub ahead of print). 29.collab: WHO. Coronavirus" exact="disease" post="(COVID-2019) situation reports. (2020). www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports 30.AlJohani S , HajeerAHMERS-CoV"/>
 <result pre="and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS" exact="Central" post="Science6(3), 315â€&quot;331 (2020).32226821 33.CormanVM , LandtO , KaiserMet al.Detection"/>
 <result pre=", SungHAnalytical and clinical validation of six commercial Middle East" exact="Respiratory" post="Syndrome coronavirus RNA detection kits based on real-time reverse-transcription"/>
 <result pre="SungHAnalytical and clinical validation of six commercial Middle East Respiratory" exact="Syndrome" post="coronavirus RNA detection kits based on real-time reverse-transcription PCR."/>
 <result pre="(2016).27374710 35.ShiratoK , YanoT , SenbaSet al.Detection of Middle East" exact="respiratory" post="syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP)."/>
 <result pre="35.ShiratoK , YanoT , SenbaSet al.Detection of Middle East respiratory" exact="syndrome" post="coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP). Virol."/>
 <result pre=", ChenT-C , YangJ-Yet al.Sensitive and quantitative detection of severe" exact="acute" post="respiratory syndrome coronavirus infection by real-time nested polymerase chain"/>
 <result pre="ChenT-C , YangJ-Yet al.Sensitive and quantitative detection of severe acute" exact="respiratory" post="syndrome coronavirus infection by real-time nested polymerase chain reaction."/>
 <result pre=", YangJ-Yet al.Sensitive and quantitative detection of severe acute respiratory" exact="syndrome" post="coronavirus infection by real-time nested polymerase chain reaction. Clin."/>
 <result pre="al.Sensitive and quantitative detection of severe acute respiratory syndrome coronavirus" exact="infection" post="by real-time nested polymerase chain reaction. Clin. Infect. Dis.38(2),"/>
 <result pre="blot assay for detection of antibodies against coronavirus causing severe" exact="acute" post="respiratory syndrome. Clin. Diagn. Lab. Immunol.11(2), 417â€&quot;422 (2004).15013997 41.HuiRK"/>
 <result pre="assay for detection of antibodies against coronavirus causing severe acute" exact="respiratory" post="syndrome. Clin. Diagn. Lab. Immunol.11(2), 417â€&quot;422 (2004).15013997 41.HuiRK ,"/>
 <result pre="transcriptase PCR diagnostic assay for the coronavirus associated with severe" exact="acute" post="respiratory syndrome. J. Clin. Microbiol.42(5), 1994â€&quot;1999 (2004).15131160 42.WuJT ,"/>
 <result pre="PCR diagnostic assay for the coronavirus associated with severe acute" exact="respiratory" post="syndrome. J. Clin. Microbiol.42(5), 1994â€&quot;1999 (2004).15131160 42.WuJT , LeungK"/>
 <result pre="study. Lancet395(10225), 689â€&quot;697 (2020). 32014114 â€¢ Initial report on the" exact="viral" post="outbreak and the identification of the novel virus. 43.PangJ"/>
 <result pre="e001105 (2019). 46.NguyenT , DuongBang D , WolffA2019 Novel Coronavirus" exact="Disease" post="(COVID-19): Paving the Road for Rapid Detection and Point-of-Care"/>
 <result pre="and immunogenicity from a phase I trial of inactivated severe" exact="acute" post="respiratory syndrome coronavirus vaccine. Antivir. Ther.12(7), 1107 (2007).18018769 52.BeigelJH"/>
 <result pre="immunogenicity from a phase I trial of inactivated severe acute" exact="respiratory" post="syndrome coronavirus vaccine. Antivir. Ther.12(7), 1107 (2007).18018769 52.BeigelJH ,"/>
 <result pre="from a phase I trial of inactivated severe acute respiratory" exact="syndrome" post="coronavirus vaccine. Antivir. Ther.12(7), 1107 (2007).18018769 52.BeigelJH , VoellJ"/>
 <result pre="RobertsCC , MillsKTet al.Safety and immunogenicity of an anti-Middle East" exact="respiratory" post="syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm,"/>
 <result pre=", MillsKTet al.Safety and immunogenicity of an anti-Middle East respiratory" exact="syndrome" post="coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation"/>
 <result pre="(2020). https://clinicaltrials.gov/ct2/show/study/NCT03721718?term=vaccine&amp;amp;cond=Mers+CoV&amp;amp;draw=2&amp;amp;rank=7 55.Efficacy and safety of hydroxychloroquine for treatment of" exact="pneumonia" post="caused by 2019-ncov (hc-ncov)2020). https://clinicaltrials.gov/ct2/show/NCT04261517 56.AhmedSF , QuadeerAA ,"/>
 <result pre="vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV" exact="Immunological" post="Studies. Viruses12(3), (2020). 57.ChenWH , HotezPJ , BottazziMEPotential for"/>
 <result pre="(RBD) recombinant protein as a heterologous human vaccine against coronavirus" exact="infectious disease" post="(COVID)-19. Hum. Vaccin. Immunother.1â€&quot;4 (2020). 58.CohenJVaccine designers take first"/>
 <result pre="recombinant protein as a heterologous human vaccine against coronavirus infectious" exact="disease" post="(COVID)-19. Hum. Vaccin. Immunother.1â€&quot;4 (2020). 58.CohenJVaccine designers take first"/>
 <result pre="virus by structure-based drug repositioning (2020). . 68.collab: Center for" exact="Disease" post="Control and Prevention. Interim clinical guidance for management of"/>
 <result pre="Interim clinical guidance for management of patients with confirmed coronavirus" exact="disease" post="(COVID-19). (2020). www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html 69.collab: World Health Organization. Clinical management"/>
 <result pre="(2020). www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html 69.collab: World Health Organization. Clinical management of severe" exact="acute" post="respiratory infection (SARI) when COVID-19 disease is suspected. March"/>
 <result pre="www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html 69.collab: World Health Organization. Clinical management of severe acute" exact="respiratory" post="infection (SARI) when COVID-19 disease is suspected. March 2020"/>
 <result pre="69.collab: World Health Organization. Clinical management of severe acute respiratory" exact="infection" post="(SARI) when COVID-19 disease is suspected. March 2020 (2020)."/>
 <result pre="Clinical management of severe acute respiratory infection (SARI) when COVID-19" exact="disease" post="is suspected. March 2020 (2020). www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected 70.NicholasJ , BeechingTEF"/>
 <result pre="(2020). www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected 70.NicholasJ , BeechingTEF , FowlerRobertBMJ Best Practice: coronavirus" exact="disease" post="2019 (COVID-19) (2020). https://bestpractice.bmj.com/topics/en-gb/3000168 71.FavalliEG , IngegnoliF , DeLucia"/>
 <result pre="IngegnoliF , DeLucia O , CincinelliG , CimazR , CaporaliRCOVID-19" exact="infection" post="and rheumatoid arthritis: faraway, so close!Autoimmun. Rev.19(5), 102523 (2020)."/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive study. Lancet395(10223), 507â€&quot;513 (2020).32007143"/>
 <result pre="of 138 hospitalized patients with 2019 novel coronavirus â€&quot; infected" exact="pneumonia" post="in Wuhan, China. JAMA323(11), 1061â€&quot;1069 (2020). 77.BerginC , PhilbinM"/>
 <result pre="O'connorM , KingFSpecific Antiviral Therapy in the Clinical Management of" exact="Acute" post="Respiratory Infection with SARS-CoV-2 (COVID-19). ww.hse.ie/eng/about/who/acute-hospitals-division/drugs-management-programme/guidelines/specific-antiviral-therapy-in-the-clinical-management-of-acute-respiratory-infection-with-sars-cov-2-covid-19.pdf 78.DongL , HuS"/>
 <result pre=", KingFSpecific Antiviral Therapy in the Clinical Management of Acute" exact="Respiratory" post="Infection with SARS-CoV-2 (COVID-19). ww.hse.ie/eng/about/who/acute-hospitals-division/drugs-management-programme/guidelines/specific-antiviral-therapy-in-the-clinical-management-of-acute-respiratory-infection-with-sars-cov-2-covid-19.pdf 78.DongL , HuS ,"/>
 <result pre="KingFSpecific Antiviral Therapy in the Clinical Management of Acute Respiratory" exact="Infection" post="with SARS-CoV-2 (COVID-19). ww.hse.ie/eng/about/who/acute-hospitals-division/drugs-management-programme/guidelines/specific-antiviral-therapy-in-the-clinical-management-of-acute-respiratory-infection-with-sars-cov-2-covid-19.pdf 78.DongL , HuS , GaoJDiscovering"/>
 <result pre="ww.hse.ie/eng/about/who/acute-hospitals-division/drugs-management-programme/guidelines/specific-antiviral-therapy-in-the-clinical-management-of-acute-respiratory-infection-with-sars-cov-2-covid-19.pdf 78.DongL , HuS , GaoJDiscovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19). Search Results Featured snippet from the web"/>
 <result pre="of print). 81.FeikinDR , SchuchatA , KolczakMet al.Mortality from invasive" exact="pneumococcal pneumonia" post="in the era of antibiotic resistance, 1995â€&quot;1997. Am. J."/>
 <result pre="print). 81.FeikinDR , SchuchatA , KolczakMet al.Mortality from invasive pneumococcal" exact="pneumonia" post="in the era of antibiotic resistance, 1995â€&quot;1997. Am. J."/>
 <result pre="Safety and Antiviral Activity of Remdesivir (GS-5734â&quot;¢) in Participants With" exact="Severe" post="Coronavirus Disease (COVID-19). (2020). https://clinicaltrials.gov/ct2/show/NCT04292899 86.BarlowA , LandolfKM ,"/>
 <result pre="Antiviral Activity of Remdesivir (GS-5734â&quot;¢) in Participants With Severe Coronavirus" exact="Disease" post="(COVID-19). (2020). https://clinicaltrials.gov/ct2/show/NCT04292899 86.BarlowA , LandolfKM , BarlowBet al.Review"/>
 <result pre="BarlowBet al.Review of Emerging Pharmacotherapy for the Treatment of Coronavirus" exact="Disease" post="2019. Pharmacotherapy (2020) (Epub ahead of print). 87.HillakerE ,"/>
 <result pre="ZengQet al.Arbidol combined with LPV/r versus LPV/r alone against Corona" exact="Virus Disease" post="2019: a retrospective cohort study. J. Infect. (2020). (Epub"/>
 <result pre="al.Arbidol combined with LPV/r versus LPV/r alone against Corona Virus" exact="Disease" post="2019: a retrospective cohort study. J. Infect. (2020). (Epub"/>
 <result pre="Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of" exact="Pneumonia" post="Caused by Novel Coronavirus. (2020). https://clinicaltrials.gov/ct2/show/NCT04260594 95.MoskalM , BekerW"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studies. Bio. Sci. Trends.14(1), 72â€&quot;73; advpub (2020)."/>
 <result pre=". 98.SahraeiZ , ShabaniM , ShokouhiS , SaffaeiAAminoquinolines Against Coronavirus" exact="Disease" post="2019 (COVID-19): Chloroquine or Hydroxychloroquine. Int J Antimicrob Agents.105945"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitro. Cell. Dis.6(1), 1â€&quot;4 (2020). 101.YaoX , YeF"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. pii:"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. pii: ciaa237"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. pii: ciaa237 (2020)."/>
 <result pre="al.COVID-19, cytokines and immunosuppression: what can we learn from severe" exact="acute" post="respiratory syndrome?Clin. Exp. Rheumatol.38(2), 337â€&quot;342 (2020).32202240 109.ContiP , RonconiG"/>
 <result pre="cytokines and immunosuppression: what can we learn from severe acute" exact="respiratory" post="syndrome?Clin. Exp. Rheumatol.38(2), 337â€&quot;342 (2020).32202240 109.ContiP , RonconiG ,"/>
 <result pre=", CaraffaAet al.Induction of pro-inflammatory cytokines (IL-1 and IL-6) and" exact="lung inflammation" post="by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J. Biol."/>
 <result pre="Van VollenhovenRet al.Tocilizumab monotherapy versus adalimumab monotherapy for treatment of" exact="rheumatoid arthritis" post="(ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet381(9877),"/>
 <result pre="VollenhovenRet al.Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid" exact="arthritis" post="(ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet381(9877),"/>
 <result pre="MoriMet al.Efficacy and safety of tocilizumab in patients with systemic-onset" exact="juvenile" post="idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III"/>
 <result pre="Proc. Natl Acad. Sci.202005615 . 115.collab: Clinicaltrials.Gov. Tocilizumab in COVID-19" exact="Pneumonia" post="(TOCIVID-19) (TOCIVID-19). (2020). https://clinicaltrials.gov/ct2/show/NCT04317092?term=tocilizumab&amp;amp;cond=Covid+19&amp;amp;draw=2&amp;amp;rank=1 116.collab: Clinicaltrials.Gov. Tocilizumab for SARS-CoV2"/>
 <result pre="Pneumonia (TOCIVID-19) (TOCIVID-19). (2020). https://clinicaltrials.gov/ct2/show/NCT04317092?term=tocilizumab&amp;amp;cond=Covid+19&amp;amp;draw=2&amp;amp;rank=1 116.collab: Clinicaltrials.Gov. Tocilizumab for SARS-CoV2" exact="Severe" post="Pneumonitis (NCT04315480). (2020). https://clinicaltrials.gov/ct2/show/NCT04315480 117.collab: Chctr.Org. Favipiravir Combined With"/>
 <result pre="(TOCIVID-19) (TOCIVID-19). (2020). https://clinicaltrials.gov/ct2/show/NCT04317092?term=tocilizumab&amp;amp;cond=Covid+19&amp;amp;draw=2&amp;amp;rank=1 116.collab: Clinicaltrials.Gov. Tocilizumab for SARS-CoV2 Severe" exact="Pneumonitis" post="(NCT04315480). (2020). https://clinicaltrials.gov/ct2/show/NCT04315480 117.collab: Chctr.Org. Favipiravir Combined With Tocilizumab"/>
 <result pre="for SARS-CoV2 Severe Pneumonitis (NCT04315480). (2020). https://clinicaltrials.gov/ct2/show/NCT04315480 117.collab: Chctr.Org. Favipiravir" exact="Combined" post="With Tocilizumab in the Treatment of novel coronavirus pneumonia"/>
 <result pre="Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus" exact="pneumonia" post="(COVID-19) - A Multicenter, Randomized, Controlled Trial (2020). www.chictr.org.cn/showprojen.aspx?proj=51126"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studies. Biosci Trends14(1), 72â€&quot;73 (2020).32074550 119.collab: Clinicaltrials.Gov."/>
 <result pre="safety of bevacizumab in severe or critical patients with COVID-19" exact="pneumonia" post="â€&quot; a multi-centered randomized controlledclinical trial. (2020). https://clinicaltrials.gov/ct2/show/NCT04305106?term=Bevacizumab&amp;amp;cond=covid+19&amp;amp;draw=2&amp;amp;rank=1 122.WangY"/>
 <result pre=", GriffinI , TuckerCet al.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory disease. Lancet395(10223), e30â€&quot;e31 (2020).32032529 133.TanD-X , KorkmazA ,"/>
 <result pre="GriffinI , TuckerCet al.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="disease. Lancet395(10223), e30â€&quot;e31 (2020).32032529 133.TanD-X , KorkmazA , ReiterRJ"/>
 <result pre="al.Differential downregulation of ACE2 by the spike proteins of severe" exact="acute" post="respiratory syndrome coronavirus and human coronavirus NL63. J. Virol.84(2),"/>
 <result pre="downregulation of ACE2 by the spike proteins of severe acute" exact="respiratory" post="syndrome coronavirus and human coronavirus NL63. J. Virol.84(2), 1198â€&quot;1205"/>
 <result pre="of ACE2 by the spike proteins of severe acute respiratory" exact="syndrome" post="coronavirus and human coronavirus NL63. J. Virol.84(2), 1198â€&quot;1205 (2010).19864379"/>
 <result pre="al.Can Chinese medicine be used for prevention of corona virus" exact="disease" post="2019 (COVID-19)? A review of historical classics, research evidence"/>
 <result pre="104743 (2020). .32145402 146.ChavezS , LongB , KoyfmanA , LiangSYCoronavirus" exact="Disease" post="(COVID-19): a primer for emergency physicians. Am. J. Emerg."/>
 <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version). Military Medical Research.7(1), 4 (2020).32029004 148.LiuC ,"/>
 <result pre="and vaccines for COVID-19 and related human coronavirus diseases. ACS" exact="Central" post="Sci.6(3), 315â€&quot;331 (2020)."/>
</results>
